Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SILVER-study
2024-517502-28-01Phase 4Authorised
- Sponsor
- Amsterdam University Medical Center
- Start
- Jan 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of vedolizumab in Crohn's disease, autoimmune colitis and inflammatory bowel disease (IBD) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Cost-effectiveness of therapeutic drug monitoring–based vedolizumab de-escalation. Planned start Jan 2025; status: authorised.
02
Drugs
vedolizumab
03
Conditions
Crohn's diseaseautoimmune colitisinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on 2024-517502-28-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517502-28-01.